Talphera (TLPH) Non Operating Interest Expenses (2010 - 2023)
Talphera (TLPH) posted Non Operating Interest Expenses of $15000.0 for Q2 2023, down 92.02% on a QoQ basis from $188000.0 in Q4 2022, and down 94.88% year-over-year from $293000.0 in Q2 2022.
Analysis
Talphera (TLPH) Non Operating Interest Expenses (2010 - 2023) Analysis & Trends
Talphera has reported Non Operating Interest Expenses for 14 years, with the latest figure at $15000.0 in Q2 2023.
- On a quarterly basis, Non Operating Interest Expenses fell 94.88% year-over-year to $15000.0 in Q2 2023; TTM through Jun 2024 was $15000.0, a 97.98% decrease from a year earlier, with the FY2023 full-year figure at $134000.0, down 87.99% from the prior year.
- Non Operating Interest Expenses was $15000.0 for Q2 2023 at Talphera, down from $188000.0 in the prior quarter.
- The five-year high for Non Operating Interest Expenses was $872000.0 in Q2 2020, with the low at $15000.0 in Q2 2023.
- Average Non Operating Interest Expenses over 5 years is $544823.5, with a median of $538000.0 recorded in 2021.
- The sharpest annual moves came in 2020 and 2023: Non Operating Interest Expenses soared 127.39% in 2020, then plunged 94.88% in 2023.
- Over 5 years, Non Operating Interest Expenses stood at $831000.0 in 2019, then fell by 9.27% to $754000.0 in 2020, then plunged by 38.06% to $467000.0 in 2021, then sank by 59.74% to $188000.0 in 2022, then slumped by 92.02% to $15000.0 in 2023.
- The last three Non Operating Interest Expenses figures came in at $15000.0 (Q2 2023), $188000.0 (Q4 2022), and $245000.0 (Q3 2022), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Interest Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.67 Bn | 192.69 Bn | 7.24 Bn | 673.00 Mn |
| 2 | Gilead Sciences | 180.06 Bn | 176.88 Bn | 6.22 Bn | 247.00 Mn |
| 3 | Vertex Pharmaceuticals | 131.44 Bn | 123.59 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 81.94 Bn | 73.95 Bn | 3.93 Bn | 11.00 Mn |
| 5 | Argenx Se | 60.28 Bn | 55.10 Bn | 1.37 Bn | -1.00 Mn |
| 6 | Moderna | 53.87 Bn | 48.73 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 33.15 Bn | 29.85 Bn | 992.69 Mn | 82.05 Mn |
| 8 | Biogen | 31.88 Bn | 30.60 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.16 Bn | 29.16 Bn | 1.16 Mn | - |
| 10 | Talphera | 93.28 Mn | 93.28 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2023 | 15,000.00 |
| Dec 31, 2022 | 188,000.00 |
| Sep 30, 2022 | 245,000.00 |
| Jun 30, 2022 | 293,000.00 |
| Mar 31, 2022 | 390,000.00 |
| Dec 31, 2021 | 467,000.00 |
| Sep 30, 2021 | 538,000.00 |
| Jun 30, 2021 | 614,000.00 |
| Mar 31, 2021 | 672,000.00 |
| Dec 31, 2020 | 754,000.00 |
| Sep 30, 2020 | 824,000.00 |
| Jun 30, 2020 | 872,000.00 |
| Mar 31, 2020 | 855,000.00 |
| Dec 31, 2019 | 831,000.00 |
| Sep 30, 2019 | 828,000.00 |
| Jun 30, 2019 | 500,000.00 |
| Mar 31, 2019 | 376,000.00 |
| Dec 31, 2018 | 459,000.00 |
| Sep 30, 2018 | 529,000.00 |
| Jun 30, 2018 | 586,000.00 |